MiR‑221 and miR‑222 regulate cell cycle progression and affect chemosensitivity in breast cancer by targeting ANXA3
Authors:
Open Access
- 7 February 2023
- journal article
- research article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 25 (3) , 1-13
Abstract
Breast malignancy remains one of the most common causes of cancer‑associated mortalities among women. MicroRNA (miR)‑221 and miR‑222 are homologous miRs and have a substantial impact on cancer progression. In the present study, the regulatory mechanisms of miR‑221/222 and its target annexin A3 (ANXA3) in breast cancer cells were investigated. Breast tissue samples were collected to evaluate the expression patterns of miR‑221/222 levels in breast cancer cell lines and cancer tissues according to clinical characteristics. The levels of miR‑221/222 were increased or decreased in cancer cell lines compared with normal breast cell lines according to cell line subtype. Subsequently, the changes in the progression and invasion of breast cancer cells were investigated using cell proliferation, invasion assay, gap closure and colony formation assays. Western blotting of cell cycle proteins and flow cytometry were performed to evaluate the possible pathway of miR‑221/222 and ANXA3 axis. Chemosensitivity tests were performed to explore the suitability of the miR‑221/222 and ANXA3 axis as a therapeutic target in breast cancer. The expression levels of miR‑221/222 were associated with aggressive characteristics of breast cancer subtypes. Cell transfection assay demonstrated the regulation of breast cancer proliferation and invasiveness by miR‑221/222. MiR‑221/222 directly targeted the 3'‑untranslated region of ANXA3 and suppressed the expression of ANXA3 at the mRNA and protein levels. In addition, miR‑221/222 negatively regulated cell proliferation and the cell cycle pathway in breast cancer cells by targeting ANXA3. In combination with adriamycin, downregulation of ANXA3 may sensitize adriamycin‑induced cell death to induction of persistent G2/M and G0/G1 arrest. Decreased expression of ANXA3 through increased expression of miR‑221/222 reduced breast cancer progression and increased the effectiveness of the chemotherapy drug. The present results indicated the miR‑221/222 and ANXA3 axis to be a possible novel therapeutic target for the treatment of breast cancer.Keywords
This publication has 38 references indexed in Scilit:
- miR-221/222 Targets Adiponectin Receptor 1 to Promote the Epithelial-to-Mesenchymal Transition in Breast CancerPLOS ONE, 2013
- Identifying Resistance Mechanisms against Five Tyrosine Kinase Inhibitors Targeting the ERBB/RAS Pathway in 45 Cancer Cell LinesPLOS ONE, 2013
- The miRNA–Drug Resistance Connection: A New Era of Personalized Medicine Using Noncoding RNA BeginsPharmacogenomics, 2012
- MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathwaysOncogene, 2010
- Increased Expression of Annexin A3 Is a Mechanism of Platinum Resistance in Ovarian CancerCancer Research, 2010
- p16promoter methylation in Pb2+-exposed individualsClinical Toxicology, 2010
- RETRACTED: miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 DownregulationCancer Cell, 2009
- MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtypeGenome Biology, 2007
- MicroRNA Gene Expression Deregulation in Human Breast CancerCancer Research, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001